Avalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% interest, has acquired DE Laboratory (DE Labs) in Houston, Texas. This acquisition expands LSM's presence in Texas and offers significant growth potential. DE Labs is a CLIA-certified and COLA-accredited laboratory that performs about 1,500 lab tests per month, focusing on toxicology and wellness testing.
LSM will operate DE Labs as a fully owned subsidiary and has invested capital for geographical expansion into surrounding counties. The acquisition aligns with Avalon's strategy to expand LSM through acquisitions and strategic relationships in the fragmented laboratory testing market. Avalon aims to target laboratories with exceptional performance, positive revenue track records, and niche-market advantages.
Avalon GloboCare Corp. (NASDAQ: ALBT) ha annunciato che Laboratory Services MSO (LSM), in cui Avalon detiene una partecipazione del 40%, ha acquisito DE Laboratory (DE Labs) a Houston, Texas. Questa acquisizione espande la presenza di LSM in Texas e offre un significativo potenziale di crescita. DE Labs è un laboratorio certificato CLIA e accreditato COLA che esegue circa 1.500 test di laboratorio al mese, concentrandosi su tossicologia e test per il benessere.
LSM opererà DE Labs come una filiale completamente posseduta e ha investito capitali per l'espansione geografica nei cantoni circostanti. L'acquisizione è in linea con la strategia di Avalon di espandere LSM attraverso acquisizioni e relazioni strategiche nel frammentato mercato dei test di laboratorio. Avalon punta a mirare a laboratori con prestazioni eccezionali, tracciabilità dei ricavi positiva e vantaggi di mercato di nicchia.
Avalon GloboCare Corp. (NASDAQ: ALBT) anunció que Laboratory Services MSO (LSM), en el que Avalon posee un interés del 40%, ha adquirido DE Laboratory (DE Labs) en Houston, Texas. Esta adquisición expande la presencia de LSM en Texas y ofrece un significativo potencial de crecimiento. DE Labs es un laboratorio certificado por CLIA y acreditado por COLA que realiza aproximadamente 1,500 pruebas de laboratorio por mes, enfocándose en toxicología y pruebas de bienestar.
LSM operará DE Labs como una subsidiaria de propiedad total y ha invertido capital para la expansión geográfica en los condados circundantes. La adquisición está alineada con la estrategia de Avalon de expandir LSM a través de adquisiciones y relaciones estratégicas en el fragmentado mercado de pruebas de laboratorio. Avalon busca laboratorios con un rendimiento excepcional, antecedentes positivos de ingresos y ventajas en mercados de nicho.
Avalon GloboCare Corp. (NASDAQ: ALBT)는 Avalon이 40%의 지분을 소유하고 있는 Laboratory Services MSO (LSM)가 텍사스 휴스턴에 있는 DE Laboratory (DE Labs)를 인수했다고 발표했습니다. 이번 인수는 LSM의 텍사스 내 존재감을 확대하고 상당한 성장 잠재력을 제공합니다. DE Labs는 CLIA 인증 및 COLA 승인 실험실로, 매달 약 1,500개의 실험실 테스트를 수행하며 독성학 및 건강 검사에 집중하고 있습니다.
LSM은 DE Labs를 완전 자회사로 운영하며 주변 카운티로의 지리적 확장을 위해 자본을 투자했습니다. 이번 인수는 분산된 실험실 테스트 시장에서 인수와 전략적 관계를 통해 LSM을 확장하고자 하는 Avalon's의 전략과 일치합니다. Avalon은 뛰어난 성능을 지닌 실험실, 긍정적인 수익 기록과 틈새 시장의 이점을 가진 실험실을 목표로 하고 있습니다.
Avalon GloboCare Corp. (NASDAQ: ALBT) a annoncé que Laboratory Services MSO (LSM), dans lequel Avalon détient une participation de 40 %, a acquis DE Laboratory (DE Labs) à Houston, Texas. Cette acquisition élargit la présence de LSM au Texas et offre un potentiel de croissance significatif. DE Labs est un laboratoire certifié CLIA et accrédité par le COLA qui effectue environ 1 500 tests de laboratoire par mois, en se concentrant sur la toxicologie et les tests de bien-être.
LSM exploitera DE Labs en tant que filiale entièrement détenue et a investi des capitaux pour une expansion géographique dans les comtés environnants. L'acquisition s'inscrit dans la stratégie d'Avalon d'élargir LSM par le biais d'acquisitions et de relations stratégiques sur le marché fragmenté des tests de laboratoire. Avalon vise à cibler les laboratoires ayant une performance exceptionnelle, des antécédents de revenus positifs et des avantages sur des marchés de niche.
Avalon GloboCare Corp. (NASDAQ: ALBT) gab bekannt, dass Laboratory Services MSO (LSM), an dem Avalon eine 40%ige Beteiligung hält, DE Laboratory (DE Labs) in Houston, Texas, erworben hat. Diese Akquisition erweitert die Präsenz von LSM in Texas und bietet erhebliches Wachstumspotenzial. DE Labs ist ein CLIA-zertifiziertes und COLA-akkreditiertes Labor, das etwa 1.500 Labortests pro Monat durchführt und sich auf Toxikologie und Gesundheitsuntersuchungen spezialisiert hat.
LSM wird DE Labs als eine vollständig im Besitz befindliche Tochtergesellschaft betreiben und hat Kapital für die geografische Expansion in die umliegenden Landkreise investiert. Die Akquisition stimmt mit Avalons Strategie überein, LSM durch Akquisitionen und strategische Beziehungen im fragmentierten Laborprüfung Markt zu erweitern. Avalon hat zum Ziel, Labore mit außergewöhnlicher Leistung, positiven Einnahmen und Vorteilen im Nischenmarkt anzusprechen.
- Acquisition of DE Laboratory expands LSM's presence in Texas
- DE Labs performs 1,500 lab tests per month, indicating established operations
- Investment in growth capital for geographical expansion into surrounding counties
- Potential for significant synergies in revenue growth and market share
- None.
DE Laboratory in Texas Performs 1,500 Lab Tests Per Month with Focus on Toxicology and Wellness Testing; Expansion Underway
FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company. Avalon owns a
DE Labs is a CLIA-certified and COLA-accredited laboratory located in Houston, Texas that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing. LSM is now operating this laboratory as a fully owned subsidiary and has invested growth capital for geographical expansion into the surrounding counties.
“This acquisition is just another step towards our goal of expanding LSM through acquisitions and strategic relationships,” commented, David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our strategy is to take advantage of a unique roll-up opportunity within the highly fragmented market for laboratory testing and services. We continue to target laboratories with exceptional performance, positive revenue track records and niche-market advantages. By leveraging LSM’s experience and infrastructure, we expect to achieve significant synergies with respect to revenue growth and market share.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is establishing a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding LSM. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ
What company did Avalon GloboCare's Laboratory Services MSO acquire?
How many tests does DE Laboratory perform monthly?
What is Avalon GloboCare's strategy for expanding Laboratory Services MSO?
What certifications does DE Laboratory hold?
